A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin

A Registry Study on the Risk Factors of Interstitial Pneumonia in Lymphoma Patients Treated With Liposomal Doxorubicin

This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.

Inclusion Criteria:

• histologically confirmed lymphoma
• 18-80 years
• ECOG<= 2
• newly diagnosed lymphoma
• liposomal doxorubicin is planned in the treatment
• normal lung function
• no history or malignancy
• informed consented

Exclusion Criteria:

• history of malignancy, now in the treatment
• pregnant
• serious infection
• other uncontrollable conditions judged by the investigator